Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Condition:   Neoplasms Interventions:   Drug: GSK3377794;   Drug: Pembrolizumab;   Drug: Fludarabine;   Drug: Cyclophosphamide Sponsors:   GlaxoSmithKline;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials